NIH-Funded Study Finds Similar Efficacy for Two Common Uveitis Treatments
For members of the inherited retinal disease (IRD) community, managing eye inflammation, such as uveitis, can be a critical part of preserving vision. While uveitis itself is distinct from IRDs, inflammation can sometimes be a co-occurring condition or a factor in overall eye health. Understanding the effectiveness of treatments for inflammatory eye conditions is therefore important for patients and their families, as it contributes to the broader landscape of ophthalmic care.
A recent clinical trial, funded by the National Institutes of Health (NIH), specifically the National Eye Institute (NEI), has provided valuable insights into the treatment of non-infectious uveitis. The study, known as the Systemic Immunosuppressive Therapy for Eye Diseases (SITE) study, compared two commonly used systemic immunosuppressive drugs: methotrexate and mycophenolate mofetil. The primary finding, as reported by the National Institutes of Health (NIH) on September 10, 2019, was that these two drugs performed similarly in controlling inflammation and preventing vision loss in patients with non-infectious intermediate, posterior, or panuveitis.
The trial included 216 participants across 33 clinical sites. Participants were randomly assigned to receive either methotrexate or mycophenolate mofetil for six months. The main outcome measured was treatment success, defined as a reduction in inflammation without worsening of vision, and without requiring additional treatments or causing unacceptable side effects. According to the NIH, both drugs achieved a similar rate of treatment success, with 47% of patients on mycophenolate mofetil and 46% of patients on methotrexate meeting this primary outcome.
Furthermore, the study found no significant differences in the rates of side effects between the two treatment groups. This suggests that both medications are comparably safe and effective for the conditions studied. The lead investigator, Dr. James T. Rosenbaum from Oregon Health & Science University, noted that the results provide clinicians with more confidence in choosing either drug, potentially allowing for decisions based on factors like patient preference, cost, or specific side effect profiles.
For patients and families navigating complex eye conditions, including IRDs, this research offers a clearer picture of treatment options for co-occurring inflammatory issues. Knowing that two established medications have similar efficacy and safety profiles can empower patients and their healthcare providers to make informed decisions tailored to individual needs. This type of evidence-based research helps refine treatment protocols and ensures that patients receive the most effective care possible.
The NEI continues to support research aimed at improving treatments for a wide range of eye diseases, including those that can impact the IRD community. Findings like these contribute to the ongoing effort to enhance patient outcomes and quality of life.